Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Unidade Local de Saúde São João
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04858009CT.gov Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | — | Recruiting | — | — | — |
NCT04701645CT.gov Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer | — | Recruiting | — | — | — |
NCT05406674CT.gov Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04811703CT.gov Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT02433626CT.gov Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneum Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Unidade Local de Saúde São João | P2 | B · 62 |
| Cyclophosphamide | Peking University | P2 | BB |
| Docetaxel | University of Pittsburgh | P2 | BB |
| Fluorouracilum | City of Hope Medical Center | P3 | BB |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Rucaparib | pharmaand GmbH | P3 | BB |
| Pembrolizumab | University College, London | P2 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Carboplatin | Qilu Hospital of Shandong University | P3 | BB |
+41 more in the Peritoneum Cancer cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Peritoneum Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-peritoneum-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →